Results for tag: "Vamorolone"

Vamorolone is a novel, investigational drug for the treatment of musculoskeletal disorders. It is a first-in-class, orally-active, non-steroidal, anti-inflammatory drug (NSAID) that has been designed to reduce inflammation and improve muscle function. Vamorolone has been studied in clinical trials for the treatment of Duchenne muscular dystrophy (DMD) and has shown promise in improving muscle strength and function. Vamorolone is being developed by ReveraGen BioPharma, Inc., a biopharmaceutical company focused on developing treatments for rare and neglected diseases. ReveraGen has partnered with pharmaceutical companies such as Pfizer, Inc. and Novartis AG to develop and commercialize Vamorolone. Vamorolone is currently in Phase 3 clinical trials for the treatment of DMD. The results of these trials will determine whether Vamorolone will be approved for use in the treatment of DMD. Companies in the Vamorolone market include ReveraGen BioPharma, Inc., Pfizer, Inc., Novartis AG, and other pharmaceutical companies. Show Less Read more